Clinical trials: Morbidity
Urinary Tract Infections
Morbidity Rate for UTI Through Use of PCR-Based Diagnosis and Management
This retrospective study is to determine if the use of PCR for detection and identification of pathogens in UTI along with antimicrobial susceptibility information, affords more efficacious treatment of UTI, as compared to…
- Trial name
- NCT04108910
- Testing
- Guidance UTI
- Volunteers
- 66,381 people
- Sponsor
- Pathnostics
Congestive Heart Failure
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function
- Trial name
- NCT00634712
- Testing
- Candesartan
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Idiopathic Pulmonary Fibrosis
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study.
- Trial name
- BUILD 3 (NCT00391443)
- Testing
- Bosentan
- Volunteers
- 616 people
- Sponsor
- Actelion
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Morbidity
A Pilot Study for Adaptation of Neospot Device for Health Care at Primary Health Facilities in Kenya
Neospot device is a 5-in-1 wearable vital signs monitor designed to measure temperature, blood pressure, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SPO2).
- Trial name
- NCT06132633
- Testing
- Neospot vitals measurement
- Where
- Kenya
- Volunteers
- 159 people
- Sponsor
- Neopenda, PBC
Heart Failure
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo.
- Trial name
- HERMES (NCT05636176)
- Testing
- Ziltivekimab
- Where
- 1,013 sites in United States, Argentina and 44 more
- Volunteers
- 4,874 people
- Sponsor
- Novo Nordisk A/S
Ventral Hernia
Hernia Repair in Multiply Morbid Patients
Support of a ventral hernia repair with a prosthetic mesh has been demonstrated to result in a diminished rate of hernia recurrence.
- Trial name
- RAM2P (NCT00930787)
- Testing
- Strattice Reconstructive Tissue Matrix (Hernia Repair), Proceed Surgical Mesh (Hernia repair)
- Where
- 13 sites in United States
- Volunteers
- 23 people
- Sponsor
- LifeCell
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Airway Morbidity, Covid19
Feasibility of the Infra-Red Illumination for Facilitation of Video Scope-tracheal Intubation
Airway securing through the placement of an endotracheal tube continues to be the definitive and the global standard management.
- Conditions
- Airway Morbidity, Covid19, Trachea
- Trial name
- NCT04991545
- Testing
- Application of Infrared (Active IRD/ IRRIS) device
- Where
- Qatar
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Ileus
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
Alvimopan is the first and currently the only FDA-approved therapy for acceleration of the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis.
- Trial name
- NCT01150760
- Testing
- Alvimopan
- Where
- United States
- Volunteers
- 7,050 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart.
- Trial name
- NCT00338260
- Testing
- MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years
- Volunteers
- 496 people
- Sponsor
- Organon and Co